A phase 1/2 safety and efficacy study of TAK‐754 gene therapy: The challenge of achieving durable factor VIII expression in haemophilia A clinical trials

Documenti analoghi

• Humanistic burden of haemophilia A without inhibitors: A cross‐sectional analysis of the HemoLIFE study
  di: María Teresa Álvarez‐Román, et al.
  Pubblicazione: (2024)
• The haemophilia joint health score for the assessment of joint health in patients with haemophilia
  di: Cihan Ay, et al.
  Pubblicazione: (2024)
• Measurement of recombinant porcine factor VIII in patients with congenital haemophilia A and inhibitors in the presence of emicizumab
  di: Christian Pfrepper, et al.
  Pubblicazione: (2024)
• Safety and efficacy of combined dual antiplatelet therapy and factor VIII prophylaxis in patients with haemophilia A after acute coronary syndrome
  di: Pasquale Agosti, et al.
  Pubblicazione: (2024)
• Acquired bleeding disorders
  di: Andreas Tiede, et al.
  Pubblicazione: (2024)